BBOT's BBO-10203 Significantly Inhibits Tumor Activity in Preclinical Studies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 10 2025
0mins
Should l Buy BBOT?
Source: Newsfilter
- Drug Development Progress: BBO-10203 selectively blocks the interaction between RAS and PI3Kα, significantly inhibiting pAKT signaling in tumor cells, demonstrating robust anti-tumor activity particularly in PIK3CA mutant breast cancer models, potentially offering new treatment options for patients.
- Clinical Trial Launch: BBOT will present progress on the BREAK-101 clinical trial at an upcoming conference, evaluating the safety and efficacy of BBO-10203 across various cancer types, with initial data expected in the first half of 2026, further enhancing the company's influence in cancer treatment.
- Safety Advantages: Unlike traditional PI3K inhibitors, BBO-10203 did not induce hyperglycemia or hyperinsulinemia upon oral administration, indicating a better safety and tolerability profile, which may allow for its combination with other targeted therapies, thereby broadening treatment options.
- Market Potential: Given the high prevalence of PIK3CA mutations in breast cancer, the development of BBO-10203 not only addresses the limitations of existing therapies but also positions the drug to capture significant market share in the future, meeting the growing demand for novel anti-cancer medications.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BBOT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BBOT
Wall Street analysts forecast BBOT stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.030
Low
18.00
Averages
22.83
High
27.00
Current: 9.030
Low
18.00
Averages
22.83
High
27.00
About BBOT
Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing the pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. Its pipeline of RAS-targeted oncology drug candidates includes BBO-8520, BBO-10203, and BBO-11818. BBO-8520 (NCT06343402) is a direct inhibitor of KRASG12C in both the ON and OFF states that is being evaluated both as monotherapy and in combination with pembrolizumab in the Phase 1 ONKORAS-101 trial for patients with KRASG12C mutant non-small cell lung cancer. BBO-10203 (NCT06625775) is an orally bioavailable small molecule that selectively and specifically blocks the physical interaction between RAS and PI3Ka, resulting in the inhibition of RAS-driven PI3Ka-AKT signaling in tumors without the risk of hyperglycemia. BBO-11818 (NCT06917079) is a panKRAS inhibitor targeting mutant KRAS in both the ON and OFF states with strong potency against KRASG12D and KRASG12V mutants.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BBO-11818: New KRAS Inhibitor Shows Promising Potential
- Preclinical Data Release: BridgeBio Oncology Therapeutics (BBOT) published preclinical data on BBO-11818, demonstrating significant tumor growth inhibition in KRAS mutant models, particularly against KRASG12D and KRASG12V mutations, indicating its potential therapeutic value for KRAS-driven tumors.
- Combination Therapy Potential: BBO-11818 shows enhanced efficacy when used in combination with other anti-tumor agents, such as BBO-10203, suggesting its importance in future treatment regimens and the potential to reshape existing treatment landscapes.
- Clinical Trial Progress: Initial data from the KONQUER-101 trial indicate promising anti-tumor activity across various tumor types, including a 56% tumor reduction in a pancreatic cancer patient, with additional data expected in the second half of 2026.
- Selectivity and Resistance: BBO-11818 exhibits over 500-fold selectivity for KRAS compared to other RAS isoforms, highlighting its potential to overcome resistance mechanisms associated with existing KRAS inhibitors, potentially offering better tolerability and therapeutic outcomes for patients.
See More
BridgeBio Oncology Reports Q4 2025 Financial Results and R&D Updates
- Financial Performance: BridgeBio Oncology reported a GAAP EPS of -$0.49 for Q4 2025, indicating challenges in profitability; however, with cash and equivalents totaling $425.5 million, the company expects to sustain operations into 2028.
- R&D Expense Increase: R&D expenses surged to $38.1 million in Q4 2025 from $19.5 million in Q4 2024, primarily driven by rising clinical trial and manufacturing costs for BBO-8520, BBO-11818, and BBO-10203, reflecting the company's commitment to drug development.
- Administrative Costs Rise: General and administrative expenses reached $5.3 million in Q4 2025, up from $2.3 million in Q4 2024, indicating adjustments related to BBOT's standalone operations and the initiation of its de-SPAC transaction.
- Net Loss Widening: The net loss for Q4 2025 was $38.8 million, nearly doubling from $19.7 million in Q4 2024, highlighting the financial pressures faced by the company as it expands its R&D and operational activities.
See More
Latest Rating Changes on Wall Street
- Kingsoft Cloud Upgrade: Goldman Sachs upgrades Kingsoft Cloud (KC) from Neutral to Buy, citing the company's potential as a key beneficiary of Xiaomi's increased AI investments, which support its ambition to integrate AI with the physical world.
- BridgeBio Initiation: Stifel initiates coverage of BridgeBio Oncology Therapeutics (BBOT) with a Buy rating and a $23 target price, indicating that the biotech company has significant room for growth in its stock price.
- Energy Fuels Upgrade: Goldman Sachs upgrades Energy Fuels (UUUU) to Buy, highlighting its ownership of the highest-grade uranium deposit in the U.S. and the White Mesa Mill, which provides a competitive edge as the only facility capable of processing both uranium and rare earth elements.
- James Hardie Upgrade: JPMorgan upgrades James Hardie Industries to Overweight from Neutral, noting that the outlook for U.S. residential new construction is in the early stages of recovery, and the stock trades at a discount to their blended price target, making it an attractive investment opportunity.
See More
BridgeBio to Present Novel Therapeutics at 44th J.P. Morgan Healthcare Conference
- Leadership Participation: BridgeBio Oncology Therapeutics will present at the 44th J.P. Morgan Healthcare Conference on January 12, 2026, at 5:15 p.m. PT, showcasing advancements in its RAS-pathway malignancy therapeutics, aimed at enhancing investor interest in the company's research direction.
- Live Webcast Availability: The presentation will be accessible via a live webcast on BBOT's website, with a replay available for at least 90 days post-event, ensuring that investors unable to attend in real-time can still access critical information.
- Company Background: BridgeBio is a clinical-stage biopharmaceutical company focused on advancing novel small molecule therapeutics targeting RAS and PI3Kα malignancies, with the goal of improving outcomes for patients with cancers driven by these two prevalent oncogenes.
- Market Potential: By presenting its research advancements at a key healthcare conference, BridgeBio not only attracts potential investors' attention but also strengthens its position in the competitive biopharmaceutical market, further propelling the clinical development of its innovative drugs.
See More
BridgeBio Oncology to Present Pipeline Advances at 44th J.P. Morgan Healthcare Conference
- Leadership Participation: BridgeBio Oncology's leadership team will present at the 44th J.P. Morgan Healthcare Conference on January 12, 2026, at 5:15 p.m. PT, showcasing advancements in their RAS-pathway malignancies research, aimed at enhancing investor interest in the company's development direction.
- Webcast Availability: The presentation will be live-streamed on BBOT's website under the 'Events' section, with a replay available for at least 90 days post-event, ensuring that investors unable to attend live can still access critical information, thereby enhancing transparency.
- Clinical Stage Drug Development: BBOT focuses on advancing small molecule therapeutics targeting RAS and PI3Kα malignancies, aiming to improve outcomes for patients with cancers driven by these two prevalent oncogenes, demonstrating the company's potential in cancer treatment.
- Investor Relations Enhancement: By participating in key healthcare conferences and providing online replays, BBOT not only strengthens its engagement with investors but also potentially attracts more funding focused on its innovative drug development, further propelling the company's growth in the biopharmaceutical sector.
See More
BridgeBio Grants 53,060 Stock Options to New Employee as Inducement
- Employee Incentive Plan: On December 10, 2025, BridgeBio awarded a new employee 53,060 non-qualified stock options at an exercise price of $12.88 per share under its 2025 Inducement Plan, aimed at attracting and retaining key talent to drive company growth.
- Equity Incentive Structure: The stock options will vest 1/4 on the employee's first anniversary and in 36 equal monthly installments thereafter, ensuring continued service and contribution, which enhances team stability and execution capabilities.
- Compliance Assurance: All stock options were granted outside of BBOT's stockholder-approved equity incentive plans, in accordance with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to compliance and transparency in talent acquisition.
- Strategic Company Positioning: As a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, BridgeBio aims to enhance the professionalism and innovation of its R&D team through such incentives, accelerating the development and market introduction of new therapeutics.
See More
BBO-11818: New KRAS Inhibitor Shows Promising Potential
- Preclinical Data Release: BridgeBio Oncology Therapeutics (BBOT) published preclinical data on BBO-11818, demonstrating significant tumor growth inhibition in KRAS mutant models, particularly against KRASG12D and KRASG12V mutations, indicating its potential therapeutic value for KRAS-driven tumors.
- Combination Therapy Potential: BBO-11818 shows enhanced efficacy when used in combination with other anti-tumor agents, such as BBO-10203, suggesting its importance in future treatment regimens and the potential to reshape existing treatment landscapes.
- Clinical Trial Progress: Initial data from the KONQUER-101 trial indicate promising anti-tumor activity across various tumor types, including a 56% tumor reduction in a pancreatic cancer patient, with additional data expected in the second half of 2026.
- Selectivity and Resistance: BBO-11818 exhibits over 500-fold selectivity for KRAS compared to other RAS isoforms, highlighting its potential to overcome resistance mechanisms associated with existing KRAS inhibitors, potentially offering better tolerability and therapeutic outcomes for patients.
See More
BridgeBio Oncology Reports Q4 2025 Financial Results and R&D Updates
- Financial Performance: BridgeBio Oncology reported a GAAP EPS of -$0.49 for Q4 2025, indicating challenges in profitability; however, with cash and equivalents totaling $425.5 million, the company expects to sustain operations into 2028.
- R&D Expense Increase: R&D expenses surged to $38.1 million in Q4 2025 from $19.5 million in Q4 2024, primarily driven by rising clinical trial and manufacturing costs for BBO-8520, BBO-11818, and BBO-10203, reflecting the company's commitment to drug development.
- Administrative Costs Rise: General and administrative expenses reached $5.3 million in Q4 2025, up from $2.3 million in Q4 2024, indicating adjustments related to BBOT's standalone operations and the initiation of its de-SPAC transaction.
- Net Loss Widening: The net loss for Q4 2025 was $38.8 million, nearly doubling from $19.7 million in Q4 2024, highlighting the financial pressures faced by the company as it expands its R&D and operational activities.
See More
Latest Rating Changes on Wall Street
- Kingsoft Cloud Upgrade: Goldman Sachs upgrades Kingsoft Cloud (KC) from Neutral to Buy, citing the company's potential as a key beneficiary of Xiaomi's increased AI investments, which support its ambition to integrate AI with the physical world.
- BridgeBio Initiation: Stifel initiates coverage of BridgeBio Oncology Therapeutics (BBOT) with a Buy rating and a $23 target price, indicating that the biotech company has significant room for growth in its stock price.
- Energy Fuels Upgrade: Goldman Sachs upgrades Energy Fuels (UUUU) to Buy, highlighting its ownership of the highest-grade uranium deposit in the U.S. and the White Mesa Mill, which provides a competitive edge as the only facility capable of processing both uranium and rare earth elements.
- James Hardie Upgrade: JPMorgan upgrades James Hardie Industries to Overweight from Neutral, noting that the outlook for U.S. residential new construction is in the early stages of recovery, and the stock trades at a discount to their blended price target, making it an attractive investment opportunity.
See More
BridgeBio to Present Novel Therapeutics at 44th J.P. Morgan Healthcare Conference
- Leadership Participation: BridgeBio Oncology Therapeutics will present at the 44th J.P. Morgan Healthcare Conference on January 12, 2026, at 5:15 p.m. PT, showcasing advancements in its RAS-pathway malignancy therapeutics, aimed at enhancing investor interest in the company's research direction.
- Live Webcast Availability: The presentation will be accessible via a live webcast on BBOT's website, with a replay available for at least 90 days post-event, ensuring that investors unable to attend in real-time can still access critical information.
- Company Background: BridgeBio is a clinical-stage biopharmaceutical company focused on advancing novel small molecule therapeutics targeting RAS and PI3Kα malignancies, with the goal of improving outcomes for patients with cancers driven by these two prevalent oncogenes.
- Market Potential: By presenting its research advancements at a key healthcare conference, BridgeBio not only attracts potential investors' attention but also strengthens its position in the competitive biopharmaceutical market, further propelling the clinical development of its innovative drugs.
See More
BridgeBio Oncology to Present Pipeline Advances at 44th J.P. Morgan Healthcare Conference
- Leadership Participation: BridgeBio Oncology's leadership team will present at the 44th J.P. Morgan Healthcare Conference on January 12, 2026, at 5:15 p.m. PT, showcasing advancements in their RAS-pathway malignancies research, aimed at enhancing investor interest in the company's development direction.
- Webcast Availability: The presentation will be live-streamed on BBOT's website under the 'Events' section, with a replay available for at least 90 days post-event, ensuring that investors unable to attend live can still access critical information, thereby enhancing transparency.
- Clinical Stage Drug Development: BBOT focuses on advancing small molecule therapeutics targeting RAS and PI3Kα malignancies, aiming to improve outcomes for patients with cancers driven by these two prevalent oncogenes, demonstrating the company's potential in cancer treatment.
- Investor Relations Enhancement: By participating in key healthcare conferences and providing online replays, BBOT not only strengthens its engagement with investors but also potentially attracts more funding focused on its innovative drug development, further propelling the company's growth in the biopharmaceutical sector.
See More
BridgeBio Grants 53,060 Stock Options to New Employee as Inducement
- Employee Incentive Plan: On December 10, 2025, BridgeBio awarded a new employee 53,060 non-qualified stock options at an exercise price of $12.88 per share under its 2025 Inducement Plan, aimed at attracting and retaining key talent to drive company growth.
- Equity Incentive Structure: The stock options will vest 1/4 on the employee's first anniversary and in 36 equal monthly installments thereafter, ensuring continued service and contribution, which enhances team stability and execution capabilities.
- Compliance Assurance: All stock options were granted outside of BBOT's stockholder-approved equity incentive plans, in accordance with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to compliance and transparency in talent acquisition.
- Strategic Company Positioning: As a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, BridgeBio aims to enhance the professionalism and innovation of its R&D team through such incentives, accelerating the development and market introduction of new therapeutics.
See More
